Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Axogen, Inc. (NASDAQ: AXGN) filings with the U.S. Securities and Exchange Commission, along with AI-assisted summaries to help interpret key disclosures. Axogen is a Minnesota-incorporated medical technology company focused on peripheral nerve repair and regeneration, and its filings offer detailed insight into financial performance, regulatory milestones, and corporate governance.
Through Axogen’s annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, risk factors, management’s discussion and analysis, and information on its portfolio of peripheral nerve repair products, including Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These reports also discuss regulatory processes, reimbursement trends, and non-GAAP measures such as EBITDA and Adjusted EBITDA.
Current reports on Form 8-K capture material events, such as Axogen’s announcements regarding FDA review timelines and approval of the Biologics License Application for Avance, quarterly financial results, changes to executive compensation arrangements, and outcomes of annual shareholder meetings. Regulation FD disclosures within 8-K filings often furnish press releases and investor presentations related to earnings and regulatory updates.
Investors can also use this page to track proxy materials and shareholder vote results on matters like director elections, long-term incentive plans, advisory votes on executive compensation, and auditor ratification. Where available, Form 4 and other insider transaction filings can be consulted to monitor trading activity by directors and officers.
The platform’s AI-powered tools summarize lengthy filings, highlight important sections, and surface items such as Avance BLA developments, risk factor changes, and capital structure information, helping readers navigate Axogen’s SEC reporting more efficiently.
Axogen, Inc. (AXGN) filed an 8-K on August 5, 2025.
The filing furnishes a press release announcing second quarter 2025 financial results (Exhibit 99.1) and a second quarter 2025 financial results presentation posted to the company website and furnished as Exhibit 99.2. The company explicitly states these items are furnished, not filed, and therefore not subject to Section 18 liability or incorporated by reference unless expressly stated in a future filing.
The report is signed by Marc Began, Executive Vice President, General Counsel and Chief Compliance Officer.
Axogen, Inc. (AXGN) – Form 4 insider filing
Director Amy McBride Wendell received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. The award is valued at $150,000 and represents the company’s standard director compensation. Each RSU converts to one common share upon vesting, which occurs in a single tranche on 06/19/2026, the one-year anniversary of the grant date. Following the transaction, Wendell’s directly held derivative position totals 14,150 RSUs; no open-market purchases or sales of common stock were reported. The filing does not indicate the adoption of a Rule 10b5-1 trading plan, and no other securities were acquired or disposed of.
Because the award is part of routine board compensation rather than an opportunistic purchase, the filing is unlikely to have a material impact on AXGN’s share price but does underscore continued alignment between the director and shareholder interests through equity-based pay.
Axogen, Inc. (AXGN) filed a Form 4 disclosing that Director Kathy Johnson Weiler received an annual equity grant of 14,150 restricted stock units (RSUs) on 06/19/2025. Each RSU converts into one share of common stock upon vesting, giving Weiler contingent rights to the same number of shares.
The grant is valued at approximately $150,000 based on Axogen’s share price at the grant date and vests in full on 06/19/2026, the one-year anniversary of the award. Following the transaction, the director beneficially owns 14,150 AXGN shares, all held directly. No shares were sold or otherwise disposed of.
The filing reflects routine board compensation, introduces no immediate cash outflow for the company, and does not materially change Axogen’s share count or insider ownership profile.
Form 4 snapshot: Axogen, Inc. (AXGN) disclosed that Director William P. Burke received 14,150 restricted stock units (RSUs) on 06/19/2025 as his annual board equity retainer, valued at approximately $150,000 on the grant date. The transaction is coded “A” (acquisition), confirming that no open-market trade occurred.
Each RSU converts to one share of common stock upon vesting, which is scheduled for 06/19/2026, the first anniversary of the grant. Until then the award remains a contingent right rather than outstanding shares.
Following the award Mr. Burke’s derivative holdings increased by 14,150 units, all held directly. The filing reports no dispositions, option exercises or sales, and does not affect the company’s share count or cash position. The grant aligns director compensation with long-term shareholder value and is routine under Axogen’s board compensation program.
Axogen, Inc. (AXGN) – Form 4 insider filing dated 20 June 2025
The document discloses that Director Alan M. Levine received an annual equity award of 14,150 restricted stock units (RSUs) on 19 June 2025. The grant carries an estimated fair value of $150,000 and converts to common stock on a one-for-one basis. All units vest in a single tranche on 19 June 2026, aligning compensation with a full year of board service. No open-market transactions occurred, and the exercise price is $0, confirming the award is strictly compensatory.
After the grant, Levine beneficially owns 14,150 derivative securities; no common shares were sold or otherwise disposed of. The reported transaction uses code “A,” indicating an award rather than a purchase or sale.
From a capital-structure perspective, the additional shares represent roughly 0.03 % dilution against Axogen’s ~43 million shares outstanding—an immaterial impact. Nonetheless, the filing provides a modestly positive governance signal by further aligning a board member’s interests with those of shareholders.
Axogen, Inc. (AXGN) – Form 4 insider filing
Director Paul Thomas received 18,867 restricted stock units (RSUs) on 19 June 2025 as part of the company’s annual equity award for board service. The award is valued at approximately $200,000 on the grant date and will vest one year later on 19 June 2026. No shares were sold or disposed of, and the RSUs convert to one share of common stock each upon vesting. Following the grant, Thomas beneficially owns 18,867 derivative securities in direct form. The filing does not disclose any cash transactions, option exercises, or changes to previously held positions.
On 18 June 2025 Axogen, Inc. (NASDAQ: AXGN) held its 2025 Annual Meeting, with 37.19 million shares (81.7% of the 45.53 million outstanding) represented. All eight directors were re-elected for one-year terms; most received >95% support, although John H. Johnson secured a lower 83.7% affirmative vote.
Key voting outcomes
- Auditor ratification —Deloitte & Touche LLP re-appointed with 99.7% support (37.04 M for, 0.04 M against).
- Say-on-pay —Executive compensation approved by 88.2% of votes cast (28.70 M for, 3.24 M against).
- Long-Term Incentive Plan —Fourth amendment increasing share reserve from 10.5 M to 13.4 M passed, but only with 52.4% support (16.74 M for, 15.21 M against), indicating heightened shareholder concern over dilution.
- Say-on-pay frequency —Investors strongly favored an annual advisory vote (96.7% support).
A total of 5.2 million broker non-votes applied to each proposal. The 8-K contains no financial performance metrics or strategic announcements; it strictly reports governance results. While all management-backed items succeeded, the narrow LTIP margin and one director’s lower support suggest rising shareholder scrutiny of compensation and equity dilution.